Literature DB >> 11781618

Double lumen port access in patients receiving allogeneic blood stem cell transplantation.

U Platzbecker1, T Illmer, M Schaich, J Freiberg-Richter, A Helwig, R Plettig, A Jenke, G Ehninger, M Bornhäuser.   

Abstract

We performed a prospective trial investigating the feasibility of a double lumen port access in 26 patients with hematological malignancies or solid tumors receiving either standard conditioning (n = 9, median age 49 years (range 19-65)) or dose-reduced conditioning (n = 17, median age 56 years (range 35-66)) followed by allogeneic blood stem cell transplantation. The port system was implanted within 3 months (n = 20, range 7-91 days) before transplantation or as indicated at different time points after transplantation (n = 6, range 28-680 days). Most infusions, including the graft itself and all blood drawings, were performed via the port. Over a cumulative duration of 5622 days (1310 days after standard conditioning (range 56-349) and 4431 days after dose-reduced conditioning (range 49-489)) two port systems of patients receiving standard conditioning were removed due to early postimplantation pocket infection on day 6 and 8 after insertion, respectively. In the dose-reduced conditioning group only one late removal (day 287) of a port was required. Most of the patients in both groups reported less pain and a higher degree of comfort compared to peripheral or central venipuncture. The use of double lumen port access during conditioning and in an outpatient setting after allogeneic hemopoietic stem cell transplantation is feasible and advantageous for both patient and medical staff. Implantation several weeks before the start of conditioning might help in avoiding early infectious complications after conventional myeloablative conditioning.

Entities:  

Mesh:

Year:  2001        PMID: 11781618     DOI: 10.1038/sj.bmt.1703285

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Central venous port systems as an integral part of chemotherapy.

Authors:  Ulf K Teichgräber; Robert Pfitzmann; Herbert A F Hofmann
Journal:  Dtsch Arztebl Int       Date:  2011-03-04       Impact factor: 5.594

Review 2.  Systematic review: malfunction of totally implantable venous access devices in cancer patients.

Authors:  Godelieve Alice Goossens; Marguerite Stas; Martine Jérôme; Philip Moons
Journal:  Support Care Cancer       Date:  2011-05-10       Impact factor: 3.603

3.  Patients' perceptions of having a central venous catheter or a totally implantable subcutaneous port system-results from a randomised study in acute leukaemia.

Authors:  Eva Johansson; Per Engervall; Hjördis Björvell; Robert Hast; Magnus Björkholm
Journal:  Support Care Cancer       Date:  2008-05-01       Impact factor: 3.603

4.  Totally implantable subcutaneous port system versus central venous catheter placed before induction chemotherapy in patients with acute leukaemia-a randomized study.

Authors:  Eva Johansson; Magnus Björkholm; Hjördis Björvell; Robert Hast; Rabbe Takolander; Per Olofsson; Lars Backman; Eddie Weitzberg; Per Engervall
Journal:  Support Care Cancer       Date:  2003-11-25       Impact factor: 3.603

5.  Safety of tunneled central venous catheters in pediatric hematopoietic stem cell recipients with severe primary immunodeficiency diseases.

Authors:  Illya Martynov; Jessica Klima-Frysch; Wolfram Kluwe; Christoph Engel; Joachim Schoenberger
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.